Spots Global Cancer Trial Database for A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
Official Title: A Phase 2 Clinica Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
Study ID: NCT02834936
Conditions
Interventions
Study Description
Brief Summary: This study is designed to evaluate the efficacy and safety of Pyrotinib in patients of advanced pre-treated Non-small cell lung cancer With HER2 Mutation. To observe objective response rate (ORR) of pyrotinib in NSCLC With HER2 Mutation. To observe Progression free survival (PFS). To assess the overall survival (OS). A secondary aim is to obtain safety information. To explore the relationship between biomarkers and the toxicity/efficacy of Pyrotinib.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
HR-BLTN-II-NSCLC Investigational Site, Beijing, , China
HR-BLTN-II-NSCLC Investigational Site, Changsha, , China
HR-BLTN-II-NSCLC Investigational Site, Guangzhou, , China
HR-BLTN-II-NSCLC Investigational Site, Hangzhou, , China
HR-BLTN-II-NSCLC Investigational Site, Harbin, , China
HR-BLTN-II-NSCLC Investigational Site, Nanjing, , China
HR-BLTN-II-NSCLC Investigational Site, Shanghai, , China
HR-BLTN-II-NSCLC Investigational Site, Suzhou, , China
HR-BLTN-II-NSCLC Investigational Site, Wuhan, , China
HR-BLTN-II-NSCLC Investigational Site, Zhengzhou, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
